Wireless biosensor technology player LifeSignals has merged with the connected health assets of Renew Health.
As a result, a new company, LifeSignals Group, has been formed and will be led by LifeSignals CEO and founder Surendar Magar. The LifeSignals Group will incorporate the LifeSignals business, and its Bangalore based subsidiary, LifeSignals (India) Private Limited. From Renew, LGI has acquired the UltraLinq cloud-based cardiology PACS platform business and the Zensor + cardiac analytics software business.
With its wide-ranging assets, LGI plans to accelerate the global adaptation of clinical-grade wireless biosensors by working with healthcare device OEMs and service providers, thereby improving healthcare delivery to currently underserved populations.
LifeSignals CEO and founder Surendar Magar said: “I am delighted to see this merger come to fruition. Combining the assets of both parties brings the scale and resources required for LifeSignals to accelerate its vision of promoting multiparameter clinical-grade wireless biosensor patches and replace the billions of “wired” biosensors that currently dominate the clinical monitoring arena. Overall, the combination of our wireless proprietary smart biosensor technology with the flexible cloud-based analytics, will enable patients and healthcare providers to receive potentially life-saving, real-time analysis of health data at a level that did not previously exist.”
Renew Health CEO Ravinder Sajwan, who will serve on the Board of Directors at the new company, said: “The Renew Group has long recognised the potential of LifeSignals to lead wireless biosensor adaptation on a global scale due to the unmatched power of its processor technology. Having made major investments in the connected health technologies that are complementary to LifeSignals biosensors, we see it as a natural progression to merge the connected health assets of Renew with LifeSignals, to create LifeSignals Group. Post-merger, Renew will concentrate its resources on the manufacture and global distribution of our unique commercial product portfolio.”